Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
Meta Cloud Ambitions Could Challenge AWS, Azure, and Google Cloud, Says Morgan Stanley 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
Foxconn Q2 Revenue Surges Nearly 40% on Strong AI Server Demand 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
AI Memory Chip Shortage Likely to Persist Despite Korea Investment Boom, Nomura Says 
The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay $235.5 million to GlaxoSmithKline Plc for selling a generic version of a heart drug, covered by the latter's patent.
In a 2-1 decision, the appeals court found “substantial evidence” that Teva induced doctors to prescribe its generic tablets.
Israeli drugmaker Teva plans to appeal and introduce additional defenses that it neither infringed nor induced doctors to infringe Glaxo’s patent.
The case arose after Teva began selling a generic version of Coreg, which Glaxo had won U.S. approval for, in 2007.
Coreg treats hypertension, left ventricular dysfunction after a heart attack, and congestive heart failure.
In 2017, a Delaware jury ordered the to pay $234.1 million for lost profit plus $1.4 million in royalties.
US District Judge Leonard Stark overturned the verdict due to other factors that could have caused doctors to prescribe Coreg.
But Circuit Judge Pauline Newman said Teva's promotional materials, product catalogs, the FDA labels, press releases, and witness testimony supported allegations of “induced infringement.”
